Abstract: China has experienced an unprecedented pandemic of corona virus disease 2019 (COVID-19) in 2020. In the background of serious public health events, clinical trials in most Chinese regions have experienced a series of tough periods such as suspension of admission and protocol violation. With resumption of work and production around the country, China has entered the post-COVID pandemic period. This article analyzes how clinical trial institutions resume professional work, and advocates to continue to strengthen the countermeasures and experience during the outbreak, such as the design of subject-centered clinical trial, comprehensively promotion of information technology, construction of professional clinical research centers and clinical research support teams, respecting evidence-based evidence and real-world evidence, optimal ethical committee review modes, and standardization of agency disaster recovery plan. These experiences should be applied to future clinical researches.

Key words: corona virus disease 2019, pandemic, clinical trial